Application of stachyose in preparation of drug for treating castration-resistant prostate cancer
AssigneeJiangnan University
InventorsRong Wang, Yongquan Chen, Lu Xu, Xiaoying Wang, Shenglong Zhu
Life of this patent
Estimating the term…
Loading patent…
AssigneeJiangnan University
InventorsRong Wang, Yongquan Chen, Lu Xu, Xiaoying Wang, Shenglong Zhu
Estimating the term…
Disclosed is an application of Stachyose in preparation of a drug for treating castration-resistant prostate cancer, belonging to the technical field of biological medicine. The disclosure proposes a new strategy of using Stachyose in combination with an androgen receptor antagonist to prepare a drug for treating CRPC for the first time, and conducts multi-angle and multi-level verification research. The drug composition of the Stachyose in combination with the androgen receptor in the disclosure can be used for treating castration-resistant prostate cancer, and significantly improves the effect of Enzalutamide on inhibiting castration-resistant prostate cancer. The natural compound is applied to the advanced stage of cancer, and has important clinical therapeutic significance.
A method of preparing a composition for treating EPI-001 (EPI)-tolerant or enzalutamide (Enza)-tolerant castration-resistant prostate cancer (CRPC), comprising:
A method for treating EPI-001 (EPI)-tolerant or enzalutamide (Enza)tolerant castration-resistant prostate cancer (CRPC), comprising:
Dependencies are inferred from the claim text.